Loading...
  • clinical
  • This Phase I/II clinical study is designed to examine the safety of Xcellerated T Cells, an activated, autologous T cell product, in study subjects undergoing an autologous peripheral blood stem cell transplant for the treatment of multiple myeloma. (knowcancer.com)
  • The mean apoptotic rates were similar between IgV(H) mutated and unmutated patients, the latter presenting a more aggressive clinical course. (ac.be)
  • Antioxidant capacity of calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: A randomized controlled clinical study. (ons.org)
  • The first cell based approach for the treatment of full-thickness cartilage or osteochondral lesions was performed in 1994 by Lars Peterson and Mats Brittberg who pioneered clinical autologous chondrocyte implantation (ACI) 5 . (jove.com)
  • A vaccine consisting of autologous tumor cells along with bacillus Calmette-Guerin (BCG) has shown a potential clinical benefit in patients with stage II colon cancer. (springer.com)
  • A recent randomized clinical trial showed that patients primed with rV-CEA and boosted with avipox-CEA had greater immune responses compared with patients receiving three 1-monthly avipox-CEA vaccinations followed by an rV-CEA vaccination. (springer.com)
  • In addition to using DCs for peptide-based vaccines, a number of other strategies, including transfection with messenger RNA, have produced specific T-cell responses in clinical trials. (springer.com)
  • In addition, several clinical trials using murine anti-idiotype antibodies as vaccines for patients with advanced colorectal cancer have shown both immunologic responses as well as clinical responses. (springer.com)
  • however, in our clinical experience based on the treatment of 24 WHIM patients seen at the National Institutes of Health (NIH) since 2006, recurrent bacterial infections continue to occur, despite the fact that the absolute neutrophil count (ANC) can be readily maintained above 500 cells/microliter by G-CSF and IgG levels can be restored to the normal range by IVIg. (clinicaltrials.gov)
  • In this case, clinical studies are designed to measure and the FDA evaluation is performed on the basis of a surrogate marker that is considered likely to predict patient benefit. (themmrf.org)
  • The marketing approval that is granted may be considered provisional, and a company may be required to complete additional clinical studies that formally demonstrate patient benefit. (themmrf.org)
  • Witzig TE: Detection of malignant cells in the peripheral blood of patients with multiple myeloma: Clinical implications and research applications. (springer.com)
  • Recently, thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid) have emerged as effective single agents, demonstrating significant clinical activity in relapsed and refractory myeloma. (cancernetwork.com)
  • This article will briefly summarize the efficacy data in myeloma with these three drugs, and discuss how they are being incorporated into standard clinical practice and clinical trials for the treatment of this disease. (cancernetwork.com)
  • ECOG
  • As lead author of a study by the Eastern Cooperative Oncology Group (ECOG), David S. Siegel, M.D., Ph.D., Co-Chief of Multiple Myeloma at the John Theurer Center, retrospectively analyzed data from the ECOG E4A03 trial. (medindia.net)
  • therapy
  • Patients must have undergone induction therapy prior to study registration, and may not have progressed following induction therapy or any other prior therapy for myeloma. (knowcancer.com)
  • The RNA harvested from myeloma cells before and after the first cycle of therapy at the HTLD level will furthermore be used to identify changes in global gene expression using the Illumina┬« HT12 array. (clinicaltrials.gov)
  • This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy. (jove.com)
  • One hundred days after auto-PBSCT, patients received consolidation therapy consisting two cycles of LEN plus low-dose DEX (Ld) and LEN maintenance therapy. (springer.com)
  • These observations suggest that LEN consolidation and maintenance therapy are effective and safe, and provide favorable response rates in patients with MM. (springer.com)